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Abstract
 .Epidermal growth factor EGF enhances fetal lung development in vivo and in vitro. Ligand binding to the EGF
receptor stimulates an intrinsic receptor tyrosine kinase initiating a signal transduction cascade. We hypothesized that
blocking EGF receptor function with tyrosine kinase inhibitors would decrease the expression of surfactant protein A in
 . human pulmonary epithelial cells. Human pulmonary adenocarcinoma cells NCI-H441 were exposed to genistein a broad
.  .range inhibitor of tyrosine kinases and tyrphostin AG1478 a specific inhibitor of EGF receptor tyrosine kinase . Genistein
 .significantly decreased surfactant protein A SP-A and SP-A mRNA levels in H441 cells without affecting cell viability.
The inhibitory effect of genistein on SP-A content was reversible. In contrast, tyrphostin AG1478 had no effect on SP-A
levels despite a greater inhibitory effect than genistein on EGF receptor tyrosine autophosphorylation. Furthermore,
treatment of H441 cells with exogenous EGF did not increase SP-A content or mRNA levels beyond baseline. We conclude
that inhibition of tyrosine kinase activity other than the EGF receptor decreases the expression of surfactant protein A at a
pretranslational level in human pulmonary adenocarcinoma cells. These results suggest the importance of tyrosine kinases in
modulating human SP-A synthesis.
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1. Introduction
 .Epidermal growth factor EGF is one of many
regulatory proteins and hormones that influence fetal
w xlung development 1,2 . EGF infused into fetal lambs
w xenhances pulmonary epithelial cell growth 3 , in-
Abbreviations: SP-A, surfactant protein-A; B , maximummax
binding capacity; EGF, epidermal growth factor; TGF-a , trans-
forming growth factor-a ; LDH, lactate dehydrogenase
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w xcreases alveolarization 4 and decreases the severity
w xof respiratory distress syndrome 4 . Prenatal adminis-
tration of EGF to fetal rabbits improves pulmonary
w xcompliance 5 and increases the production of sur-
w xfactant-associated phospholipids 6,7 . Prenatal ad-
ministration of EGF to fetal rhesus monkeys in-
 . w xcreases surfactant protein A SP-A content 8,9 ,
w xenhances differentiation of alveolar epithelium 8,9
and reduces the severity of respiratory distress syn-
w xdrome 9 . In vitro, EGF stimulates supernumerary
w xlung budding in embryonic chick lung 10 , surfac-
tant-associated phospholipid synthesis in fetal rat lung
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w x w x11 , SP-A synthesis in human fetal lung 12 , branch-
w xing morphogenesis in fetal mouse lung 13 and
alveolar type II cell differentiation of fetal rat lung
w xepithelial cells 14 .
EGF promotes fetal lung development by binding
with high affinity to a specific cell surface receptor, a
170,000 Da transmembrane glycosylated phosphopro-
w xtein with intrinsic tyrosine kinase activity 15 which
w xis essential for EGF receptor function 16 . Trans-
 .forming growth factor-a TGF-a , a polypeptide
growth factor with 40% homology to EGF, also binds
w xwith high affinity to the EGF receptor 17 . Ligand
binding to the EGF receptor stimulates tyrosine auto-
phosphorylation and subsequent tyrosine phosphory-
lation of specific substrate proteins that function as
second messengers in a signal transduction pathway
through which mitogenesis and other cellular activi-
w xties are modulated 18 .
The role of the EGF receptor in regulating human
pulmonary epithelial cell differentiation has yet to be
defined. One strategy to address this issue would be
to block human EGF receptor activity. In other
species, inhibiting EGF receptor tyrosine kinase ac-
tivity has interfered with fetal lung development.
Branching morphogenesis is inhibited in mouse em-
w xbryo lungs exposed to tyrphostin RG50864 13 , an
inhibitor of EGF receptor tyrosine kinase. Tyrphostin
and genistein also decreased thymidine incorporation
and cell proliferation in isolated rabbit type II cells
w x19 . Inhibition of EGF expression with antisense
oligonucleotides reduces branching morphogenesis in
w xmouse embryo lungs 20 and prenatal administration
of anti-mouse EGF antiserum to fetal mice inhibited
w xalveolar type II cell differentiation in vivo 21 . In
mutant mice that completely lack the EGF receptor,
the alveolar epithelium remains undifferentiated and
w xthe lungs remain inadequately inflated 22 .
However, a direct association between EGF recep-
tor function and human pulmonary epithelial cell
function has not been clearly shown. We hypothe-
sized that inhibition of EGF receptor function by
blocking tyrosine kinase activity would lead to de-
creased expression of surfactant protein A in human
pulmonary epithelial cells. To test our hypothesis we
 .measured levels of surfactant protein A SP-A and
SP-A mRNA in a human pulmonary adenocarcinoma
 . cell line NCI-H441 after exposure to genistein a
w xbroad range inhibitor of tyrosine kinases 23–25 and
tyrphostin AG1478 a highly specific inhibitor of
. w xEGF receptor tyrosine kinase 26 .
2. Materials and methods
2.1. Cell culture
The effects of genistein Upstate Biotechnology,
.Lake Placid, NY and tyrphostin AG1478
 .CALBIOCHEM, San Diego, CA on levels of sur-
 .factant protein A SP-A and SP-A mRNA were
evaluated in the human pulmonary adenocarcinoma
cell line, NCI-H441 American Type Culture Collec-
.tion, Rockville, MD . The cells were incubated in
RPMI-1640 medium with 7.5% fetal calf serum,
 .  .penicillin G 100 Urml , streptomycin 100 mgrml
 .  .and amphotericin 0.25 mgrml Gibco BRL . The
cells were maintained on 100-mm tissue culture plas-
tic dishes at 378C with 5% CO , the medium was2
changed every 2 to 3 days and the cells were passed
weekly by trypsinization 0.25% trypsin, 0.03%
EDTA, 0.25% BSA, 10% MEM in double-distilled
.water . The experiments were conducted with cells
from passage numbers 50 through 90 and the cells
 7were grown to 95% confluence approx. 1.6=10
.cellsrdish prior to treatment with genistein. 24 h
before treatment with genistein the cells were placed
in serum-free RPMI-1640 medium. The cells were
maintained in serum-free medium for all experimen-
tal conditions.
Genistein and tyrphostin AG1478 were diluted in
DMSO with the final concentration of DMSO in the
cell culture medium not exceeding 0.1%. Dose-re-
sponse experiments were conducted at the following
concentrations: genistein; 0.1, 1.0, 2.5, 5.0, 7.5 and
 .10 mgrml 0.37–37 mM and tyrphostin AG1478;
0.032, 0.316, 1.58, 3.16, 6.32, and 9.48 mgrml
 .0.1–30 mM . Additionally, the cells were exposed
to 39 mM daidzein an inactive analog of genistein,
. CALBIOCHEM , 30 mM tyrphostin A1 a negative
.control for tyrphostins, CALBIOCHEM and the ve-
 .hicle DMSO alone. A control without DMSO,
genistein or tyrphostin was prepared for all experi-
ments and used to normalize data between experi-
ments. The cells were incubated with either genistein
or tyrphostin for 24 h; harvested by gentle scraping
and pelleted by centrifugation 1000=g for 5 min at
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.48C . The cell pellet was flash frozen in liquid nitro-
gen and stored at y708C. Time-course experiments
were conducted with 10 mgrml of genistein with
cells harvested at 6, 12 and 24 h to determine SP-A
content. Cytotoxicity to genistein was evaluated by
measuring the release of lactate dehydrogenase LDH
.assay, LDL-20 kit, Sigma into the media at the
 .highest concentration of genistein 10 mgrml and
 .tyrphostin 10 mgrml used. EGF levels in both the
media and a cell homogenate protein concentration
.approximately 2 mgrml were determined by ra-
dioimmunoassay Diagnostic Systems Laboratories,
.Webster, TX .
To ensure that the effect of genistein on SP-A was
reversible, H441 cells were cultured with genistein
for 24 h, the genistein was removed and the cells
were left in culture for a second 24-h period. The
level of SP-A in those cells was then compared to
cells that had been with or without genistein for the
full 48-h culture period.
The effect of EGF treatment 0.01, 0.1, 1, 10, and
.25 ngrml over 24 h on baseline SP-A mRNA in
H441 cells was evaluated in cells prepared as previ-
ously described. Additionally, the effect of EGF on
SP-A protein content at a dose of 200 ngrml, the
same dose that stimulated EGF receptor autophos-
phorylation, was also determined in H441 cells pre-
pared as described above.
2.2. Western blot immunoanalysis of SP-A
Frozen cells were homogenized in phosphate
 .buffered saline PBS with 200 mM sodium ortho-
vanadate, 1 mM phenylmethylsulfonyl fluoride, leu-
 . peptin 8 mgrml , soybean trypsin inhibitor 50
.mgrml and 5 mM EDTA and then centrifuged
 . 600 = g for 5 min. Supernatant protein 75
.mgrlane was separated by electrophoresis on a
12.5% SDS-polyacrylamide gel, transferred to an Im-
mobilon-P membrane Millipore Corporation, Bed-
. w xford, MA and blocked as described 27 . The mem-
brane was incubated for 1 h at room temperature with
guinea pig anti-human SP-A antibodies 1:1000 dilu-
tion, which were kindly supplied by Dr. J. Snyder,
.Department of Anatomy, University of Iowa rinsed
with double-distilled water and then incubated with
sheep anti-guinea pig IgG conjugated to alkaline
phosphatase 1:2000 dilution, Boehringer Mannheim
.Corporation, Indianapolis, IN for 1 h at room tem-
w xperature then washed as previously described 27 .
The immunoreactive SP-A bands were then stained
by incubating the membrane at room temperature for
30 min in a solution containing 100 mM Tris pH
.9.5 , 100 mM NaCl, 5 mM MgCl , 165 mgrml2
5-bromo-4-chloro-3-indoyl phosphate, and 330
mgrml nitro blue tetrazolium. The membrane was
rinsed in distilled water, dried and photographed. The
relative amount of immunoreactive SP-A present in
each sample was quantitated by densitometry AM-
BIS Radioanalytic and Visual Imaging System, Am-
.bis, San Diego, CA .
2.3. Northern blot analysis of SP-A mRNA
Total RNA was isolated by the single step acid-
w xphenol-chloroform extraction method 28 . 10 mg of
total cellular RNA per condition was separated by gel
 .electrophoresis 1.2% agarose , transferred by capil-
lary action to a nylon membrane S&S Nytrane,
.Schleicher and Schuell, Keene, NH , UV cross-linked
 .UV Stratalinker 1800, Stratagene , and prehy-
w xbridized as described 29 .
Hybridization using a SP-A cDNA probe kindly
supplied by J. Whitsett, Department of Pediatrics,
.University of Cincinnati was performed to evaluate
steady-state levels of SP-A mRNA. A b-actin cDNA
 .probe ATCC was used to control for loading. The
w 32 xcDNA probes were radiolabelled with a- P de-
oxycytidine triphosphate Amersham, Arlington
. Heights, IL by random priming Boehringer
.Mannheim Corp., Indianapolis, IN . Hybridization
w xwas performed as described 29 and the amount of
hybridized radiolabel was quantitated from the gel by
a b counter AMBIS Radioanalytic and Visual Imag-
.ing System, Ambis . The reactive bands were visual-
ized by autoradiography at y708C.
2.4. Cell plasma membrane preparation
Frozen cells were homogenized in 0.3 M sucrose,
 .25 mM Tris-HCl pH 7.6 and 10 mM MgCl . The2
homogenate was centrifuged at 800=g for 10 min
and the resultant supernatant was centrifuged at
20 000=g for 20 min. The pellet plasma mem-
.branes was resuspended in buffer containing 25 mM
 .Tris-HCl pH 7.6 and 10 mM MgCl and again2
centrifuged at 20 000=g for 10 min. The remaining
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w xpellet containing the plasma membranes 30 was
resuspended in the same buffer and stored at y708C
w xafter the protein concentration was determined 31 .
w All buffers contained protease inhibitors leupeptin 8
.  .mgrml , soybean trypsin inhibitor 50 mgrml and
 .xphenylmethylsulfonyl fluoride 0.1 mM . All proce-
w xdures were performed on ice or at 48C 32 .
2.5. EGF binding assay
EGF binding was measured by incubating H441
 .cell plasma membranes 150 mg of protein with
w125 x I EGF 0.4 ng, specific activity 100 uCirmg,
.Amersham for 60 min at room temperature. The
binding reaction was terminated by rapid vacuum
filtration with specific EGF binding determined as
w xpreviously described 33 . EGF receptor number and
w xaffinity were determined by Scatchard analysis 34
of duplicate competitive binding assays performed by
w125 xmeasuring specific I EGF binding to H441 cell
plasma membranes in the presence of increasing con-
 .centrations of unlabeled EGF 0.1 nM to 1.0 mM .
Scatchard analysis was done using the computer pro-
w x w xgram Ligand 35 as modified by McPherson 36 .
2.6. Immunoprecipitation and immunoblotting of
phosphotyrosine proteins
Frozen H441 cells were thawed at room tempera-
ture and 500 mg of cell protein homogenate was
incubated with a rabbit polyclonal anti-phospho-
 .tyrosine antibody 5 mg, UBI for 2 h at room
temperature with shaking. Protein A Agarose beads
 .12.5 ml, Gibco-BRL, Gaithersburg, MD were added
and the mixture was incubated at room temperature
for 1 h with shaking. Immune complexes were pel-
leted by centrifugation, washed with 150 mM NaCl,
200 mM sodium orthovanadate, 10 mM Tris-HCl
 .pH 7.4 and repelleted. The pellet was resuspended
by boiling and the proteins were separated on a 7%
SDS-PAGE gel. The phosphotyrosine proteins were
then transferred to an Immobilon-P membrane Milli-
.pore Corporation, Bedford, MA . Nonspecific bind-
ing was blocked by an overnight incubation at 48C
with 3% nonfat dry milk in PBS. The membrane was
then incubated for 3 h at room temperature with a
mouse monoclonal anti-phosphotyrosine antibody
 .1:1000 dilution, UBI , rinsed and then incubated
with goat anti-mouse IgG conjugated to alkaline
 .phosphatase 1:2000 dilution, UBI for 1 h at room
temperature. The membrane was rinsed and the im-
munoreactive tyrosine-phosphorylated bands were vi-
sualized as previously described for the SP-A im-
munoblots. The relative amount of immunoreactive
tyrosine-phosphorylated protein visualized at 170,000
Da, which is the presumptive tyrosine-phosphorylated
EGF receptor, was quantitated by densitometry AM-
BIS Radioanalytic and Visual Imaging System, Am-
.bis .
2.7. EGF-stimulated tyrosine autophosphorylation of
EGF receptor
EGF-stimulated EGF receptor tyrosine autophos-
phorylation was determined using H441 cells that had
 7reached 95% confluence 100-mm dish, 1.6=10
.  .cellsrdish . EGF 200 ngrml was added and the
cells were incubated while rocking for 3 min at 378C
in RPMI medium with 200 mM sodium orthovana-
date to inhibit phosphatase activity. The cells were
exposed to EGF for 3 min, a period of time during
which the kinetics of autophosphorylation are linear
w x37,38 . At the end of the incubation period the cells
were harvested as previously described and stored at
y708C. Conditions studied were control, EGF-
stimulated, EGF-stimulated in the presence of DMSO
 .the vehicle , genistein treatment for 24 h and EGF-
 .stimulated after genistein treatment 24 h .
2.8. Statistical analysis
The effects of tyrosine kinase inhibitors on SP-A
protein, SP-A mRNA and tyrosine phosphorylated
EGF receptor were evaluated by ANOVA with a
Bonferroni correction where appropriate for multiple
comparisons GraphPad InStat, GraphPad Software,
.San Diego, CA . The time course experiment was
similarly analyzed with the Bonferroni P value set at
-0.05. In experiments not involving multiple com-
parisons the unpaired Student’s t test was used.
3. Results
3.1. EGF receptor acti˝ity in H441 cells
Scatchard analysis of EGF binding in H441 cells
 .Fig. 1 demonstrated the presence of high affinity
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w125 xFig. 1. Scatchard plot of competitive I EGF binding to H441
cells. Binding to the EGF receptor was linear by regression
 .analysis r sy0.908, P s0.012 . B s77 pM, K s1.05max D
nM and EGF receptor density s128 fmolrmg of membrane
protein.
EGF receptors with a K of 1.1"0.2 nM, a maxi-D
 .mum binding capacity B of 79"17 pM and amax
receptor density of 133"10 fmolrmg of membrane
 .protein mean"S.E.M., ns6 .
EGF-induced receptor autophosphorylation was
measured as an index of intrinsic tyrosine kinase
activity. H441 cells were stimulated with EGF and
the amount of EGF receptor tyrosine autophospho-
rylation was measured using antiphosphotyrosine an-
tibodies. There was a clear increase in the amount of
presumptive tyrosine phosphorylated EGF receptor
 .  .170 000 Da band with EGF stimulation Fig. 2 .
Quantitation by densitometry revealed that H441 cells
undergo a significant two-fold increase in presump-
tive EGF receptor tyrosine autophosphorylation with
 .EGF ns3, P-0.05, densitometric data not shown .
EGF was not detectable by radioimmunoassay sen-
sitive to 1 ngrml in either the media or cell ho-
mogenate.
 .Fig. 2. Effect of EGF 200 ngrml, 3 min incubation on auto-
phosphorylation of presumptive EGF receptors in H441 cells.
After incubation, the cells were homogenized and the phospho-
tyrosine proteins were immunoprecipitated and then separated on
a 7% SDS-PAGE gel, transferred and identified using antiphos-
photyrosine antibodies. EGF stimulated an increase in phosphory-
lation of a 170-kDa band consistent with an increase in autophos-
phorylated EGF receptor Cscontrol, EsEGF-stimulated, ns
.3 .
3.2. Effect of genistein on surfactant protein A con-
tent
Immunoreactive SP-A was measured in H441 cells
that had been exposed to genistein for 24 h. The
Fig. 3. Effect of genistein 2 separate ranges of concentrations;
wide: 0.1, 1.0, and 10.0 mgrml, narrow: 2.5, 5.0, and 7.5
. mgrml, 24 h incubation on surfactant protein A content SP-A,
.35 kDa band in H441 cells. After incubation, the cells were
homogenized and 75 mg of supernatant protein was separated on
a 12.5% SDS-PAGE gel, transferred and identified with guinea
 .pig anti-human SP-A antibodies. A Representative SP-A im-
 .munoblot wide range of genistein concentrations showing a
clear decrease in SP-A levels at 10 mgrml of genistein compared
 .to the DMSO-vehicle only condition. B Representative SP-A
 .immunoblot narrow range of genistein concentrations showing
a decrease in SPA levels at genistein concentrations G5.0
 .  .mgrml. Cscontrol, DsDMSO 0 mgrml genistein . C Den-
sitometric data of SP-A levels normalized to control with the
control value equal to one for each experiment. There is a
significant decrease in SP-A with increasing concentrations of
 . ).genistein one way ANOVA, P-0.001 . Significant differ-
ence in SP-A levels between these doses of genistein 5.0, 7.5,
.  ).10.0 mgrml and no genistein Bonferroni P value -0.05 ,
.mean"S.E.M., ns2–5 . Cscontrol condition without DMSO,
 .0sno genistein but the vehicle DMSO is present.
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 .Fig. 4. Time-course of genistein 10 mgrml on levels of SP-A
 .35 kDa band in H441 cells. The cells were harvested after
either 6, 12 or 24 h of treatment with genistein. The cells were
homogenized and 75 mg of supernatant protein was separated on
a 12.5% SDS-PAGE gel, transferred and identified with guinea
pig anti-human SP-A antibodies. There is a clear decrease in
SP-A levels after 24 h of exposure to genistein with no effect
 .seen after 24 h of exposure to the vehicle-DMSO a, lane 5 .
Quantitation by densitometry revealed that the time-dependent
inhibition of SP-A with genistein started after 12 h of exposure
 )and decreased significantly by 24 h b, P -0.05, mean"
.S.E.M., ns3 .
immunoblot analysis detected a 35 000 Da band con-
sistent with the human pulmonary surfactant-associ-
 .ated glycoprotein SP-A previously identified from
H441 cells as a band migrating between 28 000–
w x36 000 Da 39 . The first set of experiments involved
a control condition for normalization of data between
blots, a DMSO condition zero concentration of
.genistein and genistein at concentrations of 0.1, 1.0
 .and 10 mgrml Fig. 3A . The second set of experi-
ments involved similar conditions except genistein
was used at the intermediate concentrations of 2.5,
 .5.0 and 7.5 mgrml Fig. 3B . There was a clear
 .decrease in the amount of SP-A 35 000 Da band
present in H441 cells after treatment with 10 mgrml
of genistein for 24 h compared to the DMSO-vehicle
 .only condition Fig. 3A . Quantitation by densitom-
etry revealed that genistein significantly inhibited the
amount of SP-A isolated from H441 cells at doses
)2.5 mgrml Fig. 3C, Bonferroni P value -
). .0.05 , ns2–5 . There was a 43% decrease in
SP-A levels at a genistein dose of 2.5 mgrml uncor-
.rected P value of 0.046, ANOVA , however this
difference did not reach significance when corrected
for multiple comparisons. Still, the effect of genistein
on SP-A in H441 cells becomes evident at a concen-
 .tration between 1 and 2.5 mgrml Fig. 3C .
Daidzein, an inactive analog of genistein, at a
 .concentration of 10 mgrml 39 mM , did not de-
 .crease SP-A content in H441 cells data not shown
whereas genistein at the same dose 10 mgrml, 37
.  .mM did significantly decrease SP-A Fig. 3C . The
 .vehicle DMSO equaled 1.0"0.1 whereas daidzein
 . 10 mgrml equaled 0.97"0.2 ns3, mean"
S.E.M., representative immunoblot not shown, con-
.trol condition normalized to equal one .
The time-course for the inhibitory effect of genis-
 .tein 10 mgrml on SP-A was determined by harvest-
ing cells at 6, 12 and 24 h. There was a clear
 .Fig. 5. Effect of genistein 0–10.0 mgrml, 24 h incubation on
steady-state levels of SP-A mRNA isolated from H441 cells. a.
 . 32Northern blot of total RNA 10 mgrlane hybridized with P-
labeled human SP-A cDNA, stripped and reprobed with 32P-
labeled human b-actin cDNA. There is a clear decrease in the
steady-state level of SP-A mRNA at 10 mgrml of genistein
  .Cscontrol, DsDMSO vehicle, 0 mgrml genistein . b-actin
mRNA levels were not affected. b. Relationship between the
amount of SP-A mRNA normalized to control and the effect of
 .increasing doses of genistein on H441 cells 24 h incubation .
There is a significant decrease in steady-state levels of SP-A
)mRNA with increasing concentrations of genistein one way
.ANOVA, P -0.05 .
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 .decrease in SP-A 35 000 Da band after 24 h of
 .genistein Fig. 4a . There was no effect on SP-A
 .levels with 24 h of exposure to the vehicle DMSO .
The decrease in SP-A began after 12 h of genistein
exposure but significant inhibition did not occur until
 .after 24 h of incubation Fig. 4b .
3.3. Effect of genistein on steady-state le˝els of SP-A
mRNA
SP-A mRNA levels were measured in H441 cells
that had been exposed to genistein for 24 h. The
conditions included a control for normalization of
data between blots, a DMSO condition zero concen-
.tration of genistein and genistein at a wide range of
 .concentrations 0.1, 1.0 and 10 mgrml . Analysis of
total RNA by Northern blot identified a 2.1 kb SP-A
mRNA, consistent with previously reported human
SP-A mRNA transcripts detected in H441 cells
w x39,40 . Steady-state levels of SP-A mRNA decreased
in H441 cells after 24 h of incubation with 10 mgrml
 .of genistein Fig. 5a . Genistein had no significant
 .effect on b-actin mRNA levels Fig. 5a . Densito-
metric analysis of SP-A mRNA was performed and
the data was normalized within each blot to b-actin.
SP-A mRNA levels were normalized to control and
compared revealing a significant decrease in steady-
 .state levels of SP-A mRNA with genistein Fig. 5b .
3.4. Effect of genistein on EGF-stimulated autophos-
phorylation of the EGF receptor
We measured EGF-stimulated autophosphorylation
of EGF receptor tyrosine with and without exposure
w x  .to genistein 10 mgrml for 24 h Fig. 6 . The
 .phosphotyrosine immunoblots ns3 were quanti-
tated by densitometry and normalized so that the
control condition equaled one. The vehicle DMSO,
.  .lane 2 equaled 0.97"0.15, EGF-stimulated lane 3
 .equaled 1.3 " 0.03, genistein-exposed lane 4
equaled 0.93"0.07 and genistein-exposed cells with
 . EGF-stimulation lane 5 equaled 0.95"0.03 mean
."S.E.M. . There was a 25% decrease in the amount
of EGF-stimulated tyrosine phosphorylated EGF re-
 .ceptor 170 000 Da band, Fig. 6 in H441 cells that
 .had been exposed to genistein lane 5 compared to
cells stimulated with EGF in the absence of genistein
 .lane 3, P-0.05 . The concentration of genistein
Fig. 6. Effect of genistein on EGF-stimulated autophosphoryla-
tion of EGF receptor tyrosine in H441 cells. Representative
 .immunoblot of autophosphorylated EGF receptor 170 kDa band
using antiphosphotyrosine antibodies to detect EGF receptor
phosphotyrosine residues in H441 cells that had been incubated
 .with or without genistein 10 mgrml for 24 h . Lanes: 1, control;
 .  .2, DMSO vehicle ; 3, EGF-stimulated; 4, genistein 10 mgrml
without EGF-stimulation; 5, EGF-stimulated after incubation with
 .genistein 10 mgrml ; 6, tyrosine-phosphorylated EGF receptor
standard from A431 cells. Genistein decreased EGF-stimulated
 .receptor autophosphorylation lane 5 vs. lane 3 in H441 cells
 .densitometric data presented in Section 3.4 .
used in these experiments did not significantly affect
the amounts of other immunoreactive phospho-
tyrosine proteins present.
3.5. Re˝ersibility of the inhibitory effect of genistein
on SP-A le˝els
To ensure that the genistein-induced decrease in
SP-A was not due to cytotoxicity we cultured H441
cells with genistein for 24 h then removed the genis-
tein and incubated the same cells in fresh media for
an additional 24-h period and measured immunoreac-
tive SP-A. We compared the amount of SP-A isolated
from these cells to other cells that had been cultured
 .with either DMSO 0 mgrml genistein , genistein
 .10 mgrml or control media for 48 h. The SP-A
 .immunoblots ns3 were quantitated by densitom-
etry and normalized so that the control condition at
time 0 equaled one for each experiment. The control
 .  .24 h equaled 1.0"0.05, control 48 h equaled
 .1.0"0.11, DMSO 24 h equaled 1.0"0.07, DMSO
 .  .48 h equaled 1.1"0.06, genistein 24 h equaled
 .0.83"0.03, genistein 48 h equaled 0.66"0.05,
and reversal 24 h with genistein then an additional
. 24 h without genistein equaled 0.83"0.13 mean"
.S.E.M. . There was no difference in the level of SP-A
wafter 48 h of culture with or without DMSO Fig. 7,
 .  .xlane 5 DMSO-48 h versus lane 3 control-48 h .
Genistein significantly decreased SP-A levels after 48
wh of exposure compared to the vehicle alone Fig. 7,
 .  .lane 7 genistein-48 h versus lane 5 DMSO-48 h ,
xP-0.01, ns3 . In cells that had been exposed to
genistein for 24 h and then incubated for an addi-
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tional 24 h without genistein, SP-A levels stopped
decreasing and were 25% higher than SP-A content
in cells that remained exposed to genistein for the
w  .entire 48 h Fig. 7, lane 8 reversal versus lane 7
 .xgenistein-48 h .
Cell viability and growth were not affected by the
doses of genistein used in this study. There was no
evidence of cytotoxicity, as measured by the release
of LDH into the media, from cells cultured with 10
mgrml of genistein for 24 h compared to control
cells 54"10 versus 54"11 IUrL, mean"S.D.,
.ns2–3 . Cell growth was also not affected by genis-
tein. H441 cells were grown to 95% confluence in
35-mm dishes and then exposed to genistein 10
.  .mgrml , DMSO vehicle or the media alone for 24
h. The cells were isolated as previously described,
genomic DNA was extracted, and quantitated by
measuring the absorbance at 260 nm. Genistein did
not significantly decrease DNA content 141"36
.mgrdish compared to either the DMSO treated cells
 . 122"30 mgrdish or the control cells 158"26
.mgrdish, mean"S.D., ns5 . Additionally, we
evaluated baseline cell replication by measuring DNA
content over time in cells grown from 75% to 95%
Fig. 7. Reversibility of the inhibitory effect of genistein on SP-A
 .levels. Representative immunoblot of SP-A 35 kDa band iso-
lated from H441 cells. Lanes: 1, control-time 0; 2, control-24 h;
 .3, control-48 h, 4, DMSO vehicle -24 h; 5, DMSO-48 h; 6,
 .  .genistein 10 mgrml -24 h; 7, genistein 10 mgrml -48 h; and 8,
 .incubation with genistein 10 mgrml for 24 h then the genistein
treated media was removed and the same cells were incubated in
fresh media for an additional 24 h period. At the end of a total
culture period of 48 h the cells were harvested and SP-A was
isolated. Genistein significantly decreased SP-A levels after 48 h
of exposure compared to the vehicle alone lane 7 vs. lane 5,
.P -0.01, densitometric data presented in Section 3, ns3 . In
cells that had been exposed to genistein for 24 h and then
incubated for an additional 24 h without genistein, the level of
SP-A increased by approx. 25%, back towards baseline, as the
 .inhibitory effect of genistein on SP-A was reversed lane 8, R .
Fig. 8. Effect of tyrphostin AG1478 on basal phosphorylation of
EGF receptor tyrosine in H441 cells. Representative immunoblot
 .of phosphorylated EGF receptor presumptive 170 kDa band
using antiphosphotyrosine antibodies to detect EGF receptor
phosphotyrosine residues in H441 cells that had been incubated
with increasing doses of tyrphostin for 24 h. Lanes: 1, mol. wt.
w xmarkers; 2, control; 3, DMSO; 4, tyrphostin 10 mM ; 5, tyr-
 .  .  .phostin 20 mM ; 6, tyrphostin 30 mM ; 7, A1 30 mM -nega-
tive tyrphostin control. Tyrphostin AG1478 decreases tyrosine
phosphorylated EGF receptor in H441 cells densitometric data
.presented in Section 3 whereas tyrphostin A1 does not.
confluence in media without fetal calf serum. DNA
content, during the study time of 24 h did not signifi-
cantly increase compared to baseline, however by 48
h of culture there was a significant increase in DNA
content baseline-114"56 mgrdish, 24 h-163"16
).mgrdish, 48 h-190"10 mgrdish , mean"S.D.,
).ns5, Bonferroni P value-0.05 baseline vs. 48
.h . Thus cell replication is still occurring in serum-free
media prior to the addition of genistein.
3.6. Effect of tyrphostin AG1478 on EGF receptor
tyrosine autophosphorylation
We measured basal EGF receptor tyrosine auto-
phosphorylation after exposure to increasing doses of
 .  .tyrphostin AG1478 10–30 mM for 24 h Fig. 8 .
 .The phosphotyrosine immunoblots n s 3 were
quantitated by densitometry and normalized so that
the control condition equaled one. The vehicle
 .DMSO equaled 1.2 " 0.1, 10 mM tyrphostin
equaled 0.64"0.16, 20 mM tyrphostin equaled 0.53
"0.13 and 30 mM tyrphostin equaled 0.57"0.06
 .mean"S.E.M. . There was a significant reduction
by 50% of presumptive phosphorylated EGF receptor
 .tyrosine 170 000 Da band, Fig. 8 in H441 cells
 .exposed to tyrphostin one way ANOVA, Ps0.02 .
 .The inactive analogue, tyrphostin A1, 30 mM , did
not significantly affect the level of phosphorylated
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Fig. 9. Effect of tyrphostin AG1478 on surfactant protein A
 .SP-A, 35 kDa band in H441 cells. Representative immunoblot
of SP-A isolated from H441 cells exposed to increasing doses of
tyrphostin for 24 h. Lanes: 1, mol. wt. markers; 2, control; 3,
 . w x w xDMSO vehicle ; 4, tyrphostin 10 mM ; 5, tyrphostin 20 mM ;
w x w x6, tyrphostin 30 mM ; 7, A1 30 mM -negative tyrphostin con-
trol; 8, SP-A standard. SP-A was not affected by Tyrphostin
 .AG1478 densitometric data presented in Section 3 .
 .EGF receptor tyrosine 1.75"0.37 compared to the
 .vehicle Ps0.21 .
3.7. Effect of tyrphostin AG1478 on SP-A content
Immunoreactive SP-A was measured in H441 cells
 .exposed for 24 h to tyrphostin AG1478 10–30 mM
at the same concentration previously shown to inhibit
phosphorylation of EGF receptor tyrosine. In contrast
to genistein, tyrphostin did not significantly decrease
 .SP-A content in H441 cells Fig. 9 . The SP-A
 .immunoblots ns3 were quantitated by densitom-
etry and normalized so that the control condition
 .equaled one. The vehicle DMSO equaled 0.86"
0.07, 10 mM tyrphostin equaled 0.84"0.07, 20 mM
tyrphostin equaled 0.83"0.14, 30 mM tyrphostin
equaled 0.97"0.17 and Tyrphostin A1, an inactive
 .analogue, equaled 0.80"0.23 mean"S.E.M. .
Fig. 10. Effect of EGF on SP-A gene expression in H441 cells.
 .Northern blots of SP-A mRNA 2.1 kb isolated from H441 cells
exposed to increasing concentrations of EGF for 24 h ns4, 10
.mgrlane of total RNA . EGF did not increase steady-state levels
 .of SP-A mRNA densitometric data presented in Section 3 .
Fig. 11. Effect of EGF on SP-A protein content in H441 cells.
 .Immunoblot of SP-A 35 kDa band isolated from H441 cells
 .  .exposed to EGF 200 ngrml for 24 h ns3 . Lanes: 1, mol. wt.
 . markers; 2, control; 3, EGF 200 ngrml ; 4, control; 5, EGF 200
.  .ngrml ; 6, control; 7, EGF 200 ngrml ; 8, SP-A standard. EGF
did not increase SP-A content in H441 cells.
3.8. Effect of EGF on SP-A gene expression and
SP-A protein content in H441 cells
We measured steady-state levels of SP-A mRNA
in H441 cells that had been treated with EGF 0.01–
.  .25 ngrml for 24 h ns4 . Densitometric analysis
 .of Northern blots Fig. 10 of SP-A mRNA was
performed and the SP-A mRNA levels were normal-
ized so that the control condition equaled one. The
densitometric data ranged from 1.0"0.27 for EGF at
a dose of 0.01 ngrml to 1.2"0.33 at a dose of 25
 .ngrml mean"S.E.M., ns4 . EGF treatment did
not significantly affect steady-state levels of SP-A
mRNA in H441 cells.
Immunoreactive SP-A was measured in H441 cells
 .that had been treated with EGF 200 ngrml for 24 h
 .ns3 . The dose of EGF was the same dose that
stimulated an increase in tyrosine phosphorylated
 .EGF receptor Fig. 2 . The immunoblot analysis de-
tected a 35 000 Da band consistent with human SP-A
 .Fig. 11 . There was no significant difference in the
amount of SP-A present in H441 cells after treatment
 .with EGF 3250"538 densitometric units for 24 h
 .compared to control 3160"910 densitometric units
 .mean"S.E.M., ns3 .
4. Discussion
 .Surfactant protein A SP-A is the most abundant
of the surfactant proteins which aid in the formation
of the surface-active phospholipid monolayer that
w xprevents alveolar collapse 41 . The regulation of
SP-A synthesis is thus critical for normal lung func-
tion. EGF stimulates human SP-A expression and
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synthesis beyond basal levels in fetal lung explants
w x12 and tyrosine kinase activity is essential for EGF
w xreceptor function 16 . We hypothesized that tyrosine
kinase activity is important for the maintenance of
basal SP-A synthesis.
To study the effects of tyrosine kinase inhibition
on the regulation of human SP-A we blocked tyrosine
kinase activity in a human pulmonary adeno-
 .carcinoma cell line NCI-H441 . H441 cells synthe-
size and secrete both SP-A and SP-B and have
morphology characteristic of pulmonary epithelial
w xcells except for lamellar bodies 39,42 . Morphologi-
cally these cells are more similar to bronchiolar
w xepithelium and Clara cells 42 than to alveolar type
II cells. However, the ability to express SP-A and
SP-B, biochemical characteristics of the alveolar type
II cell, makes these cells a good model for studying
the regulation of surfactant proteins e.g., in H441
 . w xcells tumor necrosis factor-a TNFa 40 and phor-
w xbol ester 43 inhibit human SP-A and SP-B expres-
 .sion and transforming growth factor-b TGF-b in-
w x.hibits human SP-A expression 44 .
We found that inhibition of tyrosine kinase activity
with genistein decreased the amount of SP-A in H441
cells. This effect was at least partially pretranslational
and not a result of toxicity since genistein also inhib-
ited the expression of SP-A mRNA without affecting
the expression of b-actin mRNA. In contrast, tyr-
phostin AG1478 had no effect on SP-A levels despite
it having a greater inhibitory effect than genistein on
EGF receptor tyrosine autophosphorylation. These
results suggest an effect of a tyrosine kinase other
than the EGF receptor in modulating SP-A synthesis
in H441 cells.
Scatchard analysis of EGF receptor binding in
H441 cells revealed a single class of high affinity
receptors with a K of 1.1 nM. This agrees withD
values previously reported for EGF receptor affinity
w x15,18 . The receptor density of 133 fmolrmg of
membrane protein or 2000 receptors per cell is less
than the 20 000–200 000 receptors per cell found in
w xmost tissues 18 . However, since activation of only a
small fraction of EGF receptors may be needed to
w xelicit the maximal physiologic effect 45 , the ‘spare
w xreceptor’ phenomenon 46 , the small absolute num-
ber of EGF receptors found in H441 cells does not
imply a lack of physiologic significance.
EGF could not be detected in H441 cells, however
mRNA for both EGF and TGF-a were found by
 .RT-PCR data not shown . EGF-stimulated receptor
tyrosine autophosphorylation was evaluated in H441
cells as a measure of intrinsic tyrosine kinase activity.
There was a clear increase in the amount of im-
munoreactive tyrosine phosphorylated protein run-
 .ning at 170,000 Da with EGF-stimulation Fig. 2
inferring the presence of a functioning protein tyro-
sine kinase. The presence of tyrosine phosphorylated
EGF receptor at baseline, even in the absence of
added ligand, was presumptive evidence of either the
presence of endogenous ligands or constitutive phos-
w xphorylation 37 . However, the additional treatment
of H441 cells with exogenous EGF did not increase
 .the levels of SP-A mRNA Fig. 10 or SP-A content
 .Fig. 11 beyond the amounts found at baseline
w x39,42 . Thus a strategy of inhibiting tyrosine kinase
activity rather than stimulating EGF activity was
chosen for the study of human SP-A regulation in
this cell model.
 .Genistein a tyrosine kinase inhibitor at 5–10
 .mgrml 18.5–37 mM decreased SP-A content in
 .  .H441 cells Fig. 3C . Genistein 10 mgrml inhibited
 .SP-A mRNA expression Fig. 5 and decreased
EGF-stimulated phosphorylation of the EGF receptor
 .by 25% in intact H441 cells Fig. 6 . The order of
magnitude of this decrease is consistent with the 50%
decrease in EGF-stimulated phosphorylation of EGF
 .receptor caused by genistein 30 mgrml in human
w xepidermoid carcinoma A431 cells 23 . Thus the con-
centration of genistein used in these experiments was
appropriate for inhibiting EGF receptor autophospho-
rylation in an intact cell system.
The decrease in SP-A levels in H441 cells with
genistein exposure was concomitant with decreased
expression of SP-A mRNA, implying an effect at the
pretranslational stage. This agrees with the in vitro
effects of EGF on immature human fetal lung ex-
plants in which EGF stimulates SP-A mRNA expres-
w xsion and SP-A synthesis 12 . Thus it is expected that
inhibition of EGF receptor activity would lead to the
opposite effect, a decrease in SP-A, similar to the
decreased SP-A immunostaining found in the lungs
w xof EGF-deficient neonatal rats 47 .
However, tyrphostin AG1478, a highly specific
w xinhibitor of EGF receptor tyrosine kinase 26 , had no
 .effect on SP-A levels in H441 cells Fig. 9 despite it
having a greater inhibitory effect than genistein ap-
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.prox. 50% vs. 25% on EGF receptor tyrosine auto-
 .phosphorylation Fig. 8 . These two compounds have
different mechanisms of action with genistein acting
at the ATP binding site and tyrphostin acting at the
substrate binding site for EGF receptor tyrosine ki-
w xnase 23–26 . Thus, in pulmonary adenocarcinoma
cells, there exist alternate pathways for the regulation
of SP-A synthesis other than through the EGF recep-
tor since specific inhibition of EGF receptor tyrosine
kinase does not decrease SP-A expression, whereas a
more global inhibition of protein tyrosine kinase ac-
tivity with genistein does block SP-A expression. In
H441 cells, protein tyrosine kinases other than the
EGF receptor have to play an important role in
regulating SP-A synthesis. These may include many
of the nonreceptor protein tyrosine kinases from ei-
ther the Src or Jak family which are involved in the
w xsignaling pathways of numerous cytokines 48 . The
ID for genistein to inhibit pp60˝ - src tyrosine phos-50
w xphorylation is 7.0 mgrml 23 which is within the
dose range that inhibited SP-A expression in our
experiments.
The inhibitory effect of genistein on SP-A expres-
sion in H441 cells could also have resulted from the
inhibition of receptor protein tyrosine kinases other
than the EGF receptor. These include the insulin
 .receptor, the platelet-derived growth factor PDGF
 .receptor, the insulin-like growth factor-1 IGF-1 re-
 .ceptor, the fibroblast growth factor FGF receptor,
 .the colony-stimulating factor-1 CSF-1 receptor and
 . w xthe nerve growth factor NGF receptor 49 . Genis-
tein has been shown to affect tyrosine kinases other
than the EGF receptor, e.g., at a dose of 100 mM,
genistein begins to inhibit both PDGF-induced DNA
synthesis and PDGF-induced phospholipase C activa-
w xtion in mouse fibroblasts 24 . Ligands for some of
 w x w xthese receptors e.g., PDGF 50 , IGF-1 51 and FGF
w x.52 have been found in lung tissue implying the
presence of their receptors. It is possible that other
receptor protein tyrosine kinases may have been af-
fected by genistein, however the low doses of genis-
tein used make this less likely compared to the
known lower dose effects of genistein on nonreceptor
protein tyrosine kinases.
Genistein is not a pure tyrosine kinase inhibitor
since it can also inhibit serine and threonine kinases
w x24 . However, the concentration of genistein needed
for 50% inhibition of these known serine or threonine
protein kinases e.g., cAMP-dependent protein ki-
nase, protein kinase C, phosphorylase kinase, 5X-
.nucleotidase and phosphodiesterase is greater than
w x370 mM 24 , 10-fold greater than the maximal con-
centration of genistein used. Genistein has effects on
other areas of cellular metabolism that do not involve
tyrosine phosphorylation such as mitochondrial pyru-
w xvate transport and respiratory chain activity 53 .
However, the concentration needed to achieve at least
w x60% inhibition of pyruvate oxidation, 200 mM 53 ,
is still 5-fold greater than the maximal dose of genis-
 .tein 37 mM used. Thus, this suggests that the effects
of genistein on SP-A were primarily due to inhibition
of tyrosine kinase activity.
The inhibitory effect of genistein on SP-A was not
due to cytotoxicity. Genistein did not increase the
release of LDH into the media, alter DNA content or
affect the expression of the constitutive gene, b-actin.
Furthermore, the inhibitory effect of genistein on
 .SP-A content in H441 cells was reversible Fig. 7
implying a nontoxic mechanism for the decrease in
SP-A. There was a time-dependent effect of genistein
on SP-A content in H441 cells in which 24 h passed
before a significant decrease in SP-A levels occurred.
We speculate that this time frame is consistent with
decreased transcription of SP-A secondary to genis-
tein blocking a tyrosine kinase dependent signal
transduction cascade resulting in decrease expression
of the regulatory transcription factors c-fos and c-jun
w x18 . However, this speculation will need further
study since we only found a decrease in steady-state
levels of SP-A mRNA and did not directly measure
either transcriptional rates or mRNA stability.
We found that tyrosine kinase inhibition with
genistein decreases SP-A expression in H441 cells
and inhibits EGF receptor tyrosine phosphorylation,
but we are unable to ascribe the cause for the de-
crease in SP-A to decreased EGF receptor activity
alone due to the lack of an effect of tyrphostin
AG1478 on SP-A. The doses of genistein used should
have minimized its effects on other receptor protein
tyrosine kinases, but nonreceptor protein tyrosine ki-
nases may have been affected. This mechanism is
very likely since tyrphostin AG1478, a specific in-
hibitor of the EGF receptor tyrosine kinase, effec-
tively blocked EGF receptor tyrosine phosphorylation
in H441 cells without affecting the expression of
SP-A. The present study suggests that tyrosine ki-
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nases other than the EGF receptor are critically in-
volved in the regulation of human SP-A in H441
cells.
Acknowledgements
This work was supported in part by a Clinical
 .Research Grant a6-FY94-0309 from the March of
Dimes Birth Defects Foundation, a research grant
from the American Lung Association and National
Institutes of Health grants P30 HD27748 and R29
HL52055. We thank Louis DeWild for technical
assistance and John Dagle for comments on the
manuscript.
References
w x  . 1 Gross, I. 1990 Am. J. Physiol. 259 Lung Cell Mol Physiol
.3 , L337–L344.
w x2 Warburton, D., Lee, M., Berberich, M.A. and Bernfield, M.
 .1993 Am. J. Respir. Cell Mol. Biol. 9, 5–9.
w x3 Sundell, H., Serenius, F., Barthe, P., Friedman, Z., Kanarek,
 .K., Escobedo, M., Orth, D. and Stahlman, M.T. 1975
 .Pediatr. Res. 9, 371a Abstr.
w x4 Sundell, H.W., Gray, M.E., Serenius, F.S., Escobedo, M.B.
 .and M.T. Stahlman, M.T. 1980 Am. J. Pathol. 100, 707–
726.
w x5 Catterton, W.Z., Escobedo, M.B., Sexson, W.R., Gray, M.E.,
 .Sundell, H.W. and Stahlman, M.T. 1979 Pediatr. Res. 13,
104–108.
w x6 Haigh, R.M., Hollingsworth, M., Micklewright, L.A., Boyd,
 .R.D.H. and D’Souza, S.W. 1988 J. Dev. Physiol. 10,
433–443.
w x  .7 Higuchi, M., Hirano, H. and Maki, M. 1989 Tohoku. J.
Exp. Med. 159, 15–22.
w x8 Plopper, C.G., St. George, J.A., Read, L.C., Nishio, S.J.,
Weir, A.J., Edwards, L., Tarantal, A.F., Pinkerton, K.E.,
Merritt, T.A., Whitsett, J.A., George-Nascimento, C. and
 . Styne, D. 1992 Am. J. Physiol. 262 Lung Cell Mol.
.Physiol. 6 , L313–L321.
w x9 Goetzman, B.W., Read, L.C., Plopper, C.G., Tarantal, A.F.,
George-Nascimento, C., Merritt, T.A., Whitsett, J.A. and
 .Styne, D. 1994 Pediatr. Res. 35, 30–36.
w x  .10 Goldin, G.V. and Epperman, L.A. 1980 J. Embryol. Exp.
Morphol. 60, 235–243.
w x11 Gross, I., Dynia, D.W., Rooney, S.A., Smart, D.A., War-
 .shaw, J.B., Sissom, J.F. and Hoath, S.B. 1986 Pediatr.
Res. 20, 473–477.
w x12 Whitsett, J.A., Weaver, T.E., Lieberman, M.A., Clark, J.C.
 .and Daugherty, C. 1987 J. Biol. Chem. 262, 7908–7913.
w x13 Warburton, D., Seth, R., Shum, L., Horcher, P.G., Hall,
 .F.L., Werb, Z. and Slavkin, H.C. 1992 Dev. Biol. 149,
123–133.
w x  .14 Fraslon, C. and Bourbon, J.R. 1992 Biochim. Biophys.
Acta 1123, 65–75.
w x  .15 Carpenter, G. 1984 Cell 37, 357–358.
w x16 Chen, W.S., Lazar, C.S., Poenie, M., Tsien, R.Y., Gill, G.N.
 .and Rosenfeld, M.G. 1987 Nature 328, 820–823.
w x  .17 King, R.J., Jones, M.B. and Minoo, P. 1989 Am. J.
Physiol. 257, L23–L38.
w x  .18 Todderud, G. and Carpenter, G. 1989 Biofactors 2, 11–15.
w x  .19 Chess, P.R., Ryan, R.M. and Finkelstein, J.N. 1994 Pedi-
atr. Res. 36, 481–486.
w x20 Seth, R., Shum, L., Wu, F., Wuenschell, C., Hall, F.L.,
 .Slavkin, H.C. and Warburton, D. 1993 Dev. Biol. 158,
555–559.
w x21 Yasui, S., Nagai, A., Oohira, A., Iwashita, M. and Konno,
 .K. 1993 Pediatr. Pulmonol. 15, 251–256.
w x  .22 Sibilia, M. and Wagner, E.F. 1995 Science 269, 234–238.
w x23 Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watan-
 .abe, S., Itoh, N., Shibuya, M. and Fukami, Y. 1987 J.
Biol. Chem. 262, 5592–5595.
w x  .24 Akiyama, T., and Ogawara, H. 1991 Methods Enzymol.
201, 362–370.
w x25 Peterli, S., Stumpf, R., Schweizer, M., Sequin, U., Mett, H.´
 .and Traxler, P. 1992 Helv. Chim. Acta 75, 696–706.
w x  .26 Osherov, N. And Levitzki A, 1994 Eur. J. Biochem. 225,
1047–1053.
w x  .27 Snyder, J.M. and Mendelson, C.R. 1987 Endocrinology
120, 1250–1257.
w x  .28 Chomczynski, P. and Sacchi, N. 1987 Anal. Biochem.
162, 156–159.
w x  .29 Dekowski, S.A. and Snyder, J.M. 1992 Endocrinology
131, 669–676.
w x30 Morishige, W.K., Uetake, C., Greenwood, F.C. and Akaka,
 .J. 1977 Endocrinology 100, 1710–1722.
w x31 Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J.
 .1951 J. Biol. Chem. 193, 265–275.
w x  .32 Thompson, J.F. 1988 Am. J. Physiol. 254, G429–G435.
w x  .33 Klein, J.M. and Nielsen, H.C. 1993 J. Clin. Invest. 91,
425–431.
w x  .34 Scatchard, G. 1949 Ann. N.Y. Acad. Sci. 51, 660–672.
w x  .35 Munson, P.J. and Rodbard, D. 1980 Anal. Biochem. 107,
220–239.
w x  .36 McPherson, G.A. 1985 Kinetic, EBDA, Ligand, Lowry: A
Collection of Radioligand Binding Analysis Programs, pp.
14–96, Elsevier, Amsterdam.
w x  .37 Bowen, S., Stanley K., Selva E. and Davis, R.J. 1991 J.
Biol. Chem. 266, 1162–1169.
w x  .38 Nair, N., Davis R.J. and Robinson, H.L. 1992 Mol. Cell.
Biol. 12, 2010–2016.
w x39 O’Reilly, M.A., Gazdar, A.F., Morris, R.E. and Whitsett,
 .J.A. 1988 Biochim. Biophys. Acta 970, 194–204.
w x40 Wispe, J.R., Clark, J.C., Warner, B.B., Fajardo, D., Hull,´
 .W.E., Holtzman, R.B. and Whitsett, J.A. 1990 J. Clin.
Invest. 86, 1954–1960.
( )J.M. Klein, T.A. McCarthyrBiochimica et Biophysica Acta 1355 1997 218–230230
w x  .41 Weaver, T.E. and Whitsett, J.A. 1991 Biochem. J. 273,
249–264.
w x42 O’Reilly, M.A., Weaver, T.E., Pilot-Matias, T.J., Sarin,
 .V.K., Gazdar, A.F. and Whitsett, J.A. 1989 Biochim.
Biophys. Acta 1011, 140–148.
w x43 Pryhuber, G.S., O’Reilly, M.A., Clark, J.C., Hull, W.M.,
 .Fink, I. and Whitsett, J.A. 1990 J. Biol. Chem. 265,
20822–20828.
w x44 Whitsett, J.A., Budden, A., Hull, W.M., Clark, J.C. and
 .O’Reilly, M.A. 1992 Biochim. Biophys. Acta 1123, 257–
262.
w x45 Gazit, A., Osherov, N., Posner, I., Yais, P., Poradosu, E.,
 .Gilon, C., and Levitzki, A. 1991 J. Med. Chem. 34,
1896–1907.
w x  .46 Limbird, L.E. 1986 Cell Surface Receptors: A Short Course
on Theory and Methods, pp. 12–13, Martinus Nijhoff,
Boston.
w x47 Raaberg, L., Nexø, E., Jørgensen, P.E., Poulsen, S.S. and
 .Jakab, M. 1995 Pediatr. Res. 37, 175–181.
w x  .48 Taniguchi, T. 1995 Science 268, 251–255.
w x  .49 Cadena, D.L. and Gill, G.N. 1992 FASEB J. 6, 2332–2337.
w x50 Han, R.N.N., Mawdsley, C., Souza, P., Tanswell, A.K. and
 .Post, M. 1992 Pediatr. Res. 31, 323–329.
w x  .51 Snyder, J.M. and D’Ercole, A.J. 1987 Exp. Lung Res. 13,
449–458.
w x  .52 Han, R.N.N., Liu, J., Tanswell, A.K. and Post, M. 1992
Pediatr. Res. 31, 435–440.
w x53 Young, S.W., Poole, R.C., Hudson, A.T., Halestrap, A.P.,
 .Denton, R.M. and Tavare, J.M. 1993 FEBS Lett. 316,
278–282.
